The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
CD4+CD25+T cells responding to serologically defined autoantigens suppress antitumor immune responses
Open accessAbstract
A variety of tumor-derived antigens have been defined by IgG antibodies in tumor bearers' sera with serological identification of antigens by recombinant expression cloning (SEREX), a serological expression cloning method. The majority of these antigens show no structural abnormality and seem to be wild-type autoantigens. Coimmunization with DNA encoding these autoantigens and tumor-specific cytotoxic T lymphocytes epitopes heightened CD8+T cell responses and increased resistance to tumor challenge in a CD4+T cell-dependent manner. In contrast, immunization with these SEREX-defined autoantigens alone leads to heightened susceptibility to tumor challenge. This suppressive effect of immunization is mediated by CD4+CD25+T cells. In mice immunized with one of the SEREX-defined autoantigens, Dna J-like 2, the number of α-GalCer/CD1d tetramer+CD3+T cells [representing natural killer T (NKT) cells] was reduced in the pulmonary compartment, whereas no evident change in the number of other T cell subsets was observed. Experiments with Jα281–/–mice lacking most NKT cells indicate that NKT cells are primarily responsible for metastasis suppression and that their activity is inhibited by immunization with Dna J-like 2. We propose that SEREX identifies a pool of autoantigens that maintains and regulates immunological homeostasis via CD4+CD25+regulatory T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
CD1d-Restricted and TCR-Mediated Activation of V α 14 NKT Cells by Glycosylceramides
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., et al. (1997) · Science · doi:10.1126/science.278.5343.1626 · Cited by 2,400
Self-citationShimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
Cited by
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationSakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor?
Curotto de Lafaille, M. A., & Lafaille, J. J. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.002 · Cited by 1,055
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue, Y., & Nishikawa, H. (2019) · Cancer Science · doi:10.1111/cas.14069 · Cited by 1,041
Self-citationTOWARD AN UNDERSTANDING OF NKT CELL BIOLOGY: Progress and Paradoxes
Kronenberg, M. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115742 · Cited by 1,029
Self-citationRegulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Self-citationGoing both ways: Immune regulation via CD1d-dependent NKT cells
Godfrey, D. I., & Kronenberg, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200423594 · Cited by 877
Self-citationSmyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Beyer, M., & Schultze, J. L. (2006) · Blood · doi:10.1182/blood-2006-02-002774 · Cited by 732
Allergen-responsive CD4+CD25+ Regulatory T Cells in Children who Have Outgrown Cow's Milk Allergy
Karlsson, M. R., Rugtveit, J., & Brandtzaeg, P. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032121 · Cited by 506
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07003-x · Cited by 386
Intricacies of TGF-β signaling in Treg and Th17 cell biology
Wang, J., Zhao, X., & Wan, Y. Y. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01036-7 · Cited by 356
Chapter 8 The Role of NKT Cells in Tumor Immunity
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00408-9 · Cited by 316
Heme oxygenase-1 in tumor biology and therapy
Was, H., Dulak, J., & Jozkowicz, A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011551 · Cited by 259
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Stultz, J., & Fong, L. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00340-5 · Cited by 242
Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer
Ren, L., Yu, Y., Wang, L., Zhu, Z., Lu, R., & Yao, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12409 · Cited by 149
Met, Ö., Balslev, E., Flyger, H., & Svane, I. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0844-9 · Cited by 51
“among cancer patients in terms of efficacy and intensity of antitumor immunity remains to be elucidated and could be related to mechanisms such as the action of regulatory T cells [29], Fas-mediated apoptosis induction in CTLs [30] and antigen down-regulation by the tumor [31].”
BackgroundThe MR1/MAIT cell axis in CNS diseases
Shrinivasan, R., Wyatt-Johnson, S. K., & Brutkiewicz, R. R. (2024) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2023.12.029 · Cited by 12
Metadata
- Authors
- Nishikawa, H., Kato, T., Tanida, K., Hiasa, A., Tawara, I., Ikeda, H., Ikarashi, Y., Wakasugi, H., Kronenberg, M., Nakayama, T., Taniguchi, M., Kuribayashi, K., Old, L. J., & Shiku, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-08-28
- Volume
- 100
- Issue
- 19
- Pages
- 10902-10906
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1984393957
- Cited by
- 168
- References
- 5
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.